RA bought at 2.53 short time before so they made over 5m and did very well......
can't do it in America, and can't be listed on US exchanges....Looks like his pyramid scheme of taking people's monies and betting wildly will now move off shore.............interesting
Exubera was supposed to revolutionize DIABETES CARE. It was the first inhalable insulin product on the market, invented by biotech startup Nektar Therapeutics (NKTR) and shepherded to market by drug giant Pfizer (PFE), which predicted it would eventually bring in $2 billion a year in sales.
and that was with all the shortfalls of Exubera
about time..................he admits defeat
That will be the splitting of the company into a royalty company and a device company. This should include a 7:1 dividend ie: MNKD shareholders will get one share for every 7 they own, this will be the short squezzer...
major BP partnership with 500m upfront cash with 32% royalties increasing upon reaching certain milestones
with up to a 36% royalty with sales greater than 3B. A split in the companies first company the royalty company (Alfrezza) forming the partnership with a UK or Euro partner with a presence in Ireland (nominal tax on royalty revenues). Second company would be the device company ie: MannKind Technologies, current MNKD shareholders will receive a 7-1 ratio dividend based off of MNKD shares in the new company. So if you own 100 shares of MNKD you will receive 7 shares of the technology company. New stock is a public company which gets split off with a market value of 6 or 7 dollars. Much of the 500m received will support the new company valuation. MNKD moves to 14 or 15 initially until sales dictate a stronger move higher. Thats how i think it should workout...,,
so if that is a monetary amount (Euros) what would be the gross revenue based off of that 120euro cost? Anyone know of the wholesale weight for human insulin and how much is used in each inhaler??
MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
MannKind Corporation (MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014.
Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, and Corporate Vice President and Chief Financial Officer, Matthew Pfeffer.
docnaz123 • Jul 10, 2014 8:11 PM Flag
3users liked this postsusers disliked this posts0Reply
No-one knows when the announcement will come.
The deal between the two parties has been done.
That is why the shares have not fallen much.
There are definite sellers but the shares are being bought up.
Longs stay with it. This will come very good shortly. Remember to take your profits though.
and to add to my prior post THRX which develops the COPD products for GSK just split into two companies. Theravance and Theravance biologics. Theravance is the royalty arm and the biologics is the development arm. GSK owns a very large position in THRX I believe over 30m shares out of 110m outstanding. I wouldn't mind seeing the same situation with MNKD, this way you would have support in the stock with GSK always buying shares in the open market........
Afrezza and Technosphere. GSK works hand and hand with THRX for all kinds of COPD inhalers. Now these inhalers are multi multi billion dollar product (s). Advair inhaler was in the top 3 for many years as the highest revenue generated drug. GSK located in London, close to where Docnaz123 reported his partnership thoughts earlier in the month. This would be a match in heaven, competition is heating up in the COPD marketplace, a SOLE proprietorship with Technosphere can bring many billions to GSK... Just my thoughts.... And for another time I'll discuss the extreme short interest in ARNA that mirrors MNKD shorts.....pssss.....GSK was thought to takeout ARNA.........